16
Participants
Start Date
July 30, 2009
Primary Completion Date
May 31, 2010
Study Completion Date
May 31, 2010
Bosutinib
400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
Letrozole
2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
Letrozole
2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
"Orszagos Onkologiai Intezet B Belgyogyaszati osztaly", Budapest
AZ Sint-Augustinus, Wilrijk
Joliet Oncology Hematology Associates, Joliet
Oncology Specialists SC, Niles
Henry Ford Health System, Detroit
American Institute of Research, Whittier
Cancer Hospital, Academy of Med Science and Peking Union Med, Beijing
Johns Hopkins Singapore International Medical Centre, Singapore
Massachusetts General Hospital, Boston
UNIMED Medical Institute, Hong Kong
Centrum Medyczne Ostrobramska Niepubliczny Zaklad Opieki Zdr, Warsaw
Lead Sponsor
Pfizer
INDUSTRY